Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 20

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 20
---
 may experience different
outcomes in their investment results. We
will have discretion, subject to market demand,
to vary the timing, prices, and numbers of shares sold, and there
is no maximum sales price. Pursuant to the Sales
Agreement, our board of directors, or a duly authorized executive committee
thereof, may authorize,
from time to time, a minimum sales price per share of our Common
Stock sold in this offering, which will limit our ability
to make sales if the price goes below
that minimum. Investors may experience a decline
in the value of their shares as a result of share
sales made at prices lower than the prices they
paid.

We will need to raise substan tial additional capital in the future to fund our operations and you may expe rience further dilution if we issue additional equity securi ties in future fundraising transactions.

We
will need to raise substantial additional capital
in the future to fund our operations. To raise
additional capital, we may in the future offer
additional shares of our Common Stock or other securities
convertible into or exchangeable for our Common
Stock at prices
that may not be the same as the price per share in this offering. We
may sell shares or other securities in any other
offering at a price per share that is less than
the price per share paid by investors in this
offering, and investors purchasing shares
or other securities in the
future could have rights superior to existing
stockholders. The price per share at which we sell additional shares of our Common
Stock, or securities convertible or exchangeable into
Common Stock, in future transactions may be higher or lower than the price per share paid
by investors in this offering. Further, the exercise
of outstanding stock options and warrants may
result in further dilution of your investment.

<div align='center'>S-12

USE OF PROCEEDS</div>

We
may issue and sell shares of Common Stock having aggregate sales proceeds
of up to $11,702,826 from time to time, before deducting
sales agent commissions and estimated expenses
payable by us. The amount of proceeds from this
offering will depend upon the number of shares
of our Common Stock sold and the market price at which they
are sold. There can be no assurance that we will
be able to sell any shares under or fully utilize
the Sales Agreement with Dawson James as a source
of financing. We will retain